Resolvin D4 (RvD4, 4S,5R,17S-trihydroxy-6E,8E,10Z,13Z,15E,19Z-docosahexaenoic acid) is a stereospecific SPM biosynthesized from DHA through sequential Lipoxygenase reactions. RvD4 actively terminates inflammation and promotes tissue repair through receptor-mediated signaling cascades that reduce neutrophil infiltration, enhance efferocytosis, and stimulate wound healing β all without inducing immune suppression.
Imagine inflammation as a construction site where debris keeps piling up after demolition work. The neutrophils are demolition crews who've done their job breaking down damaged structures, but now they're standing around in the rubble, occasionally knocking down more walls out of habit. RvD4 is the site foreman who shows up with three specific instructions on their clipboard: First, send a message to the dispatch center (the bone marrow) to stop sending more demolition crews. Second, activate the cleanup teams (macrophages) who specialize in hauling away the debris β including the demolition workers themselves who've finished their shift. Third, signal the reconstruction contractors to start rebuilding while the site is being cleared. Unlike a shutdown order (immunosuppression), which would fire everyone and leave the rubble, RvD4 orchestrates an elegant transition from demolition to reconstruction, ensuring the site becomes functional tissue again rather than a chronic disaster zone.
RvD4 biosynthesis begins with DHA released from membrane phospholipids via PLA2. The pathway involves sequential oxygenation:
graph TD
A["DHA 22:6n-3"] -->|5-LOX| B[4S-hydroperoxy-DHA]
B -->|enzymatic reduction| C[4S-hydroxy-DHA intermediate]
C -->|15-LOX| D[4S,5R-dihydroxy intermediate]
D -->|enzymatic epoxidation/hydrolysis| E["RvD4: 4S,5R,17S-trihydroxy-DHA"]
E -->|binds| F[Cell surface receptors]
F -->|GPR-coupled| G[Intracellular signaling]
G --> H["β NF-ΞΊB activation"]
G --> I["β Neutrophil chemotaxis"]
G --> J["β Macrophage efferocytosis"]
G --> K["β Pro-inflammatory cytokines"]
G --> L["β Tissue repair programs"]
Detailed Cascade:
-
Biosynthesis: 5-LOX converts DHA β 4S-hydroperoxy-DHA β 4S-hydroxy intermediate. 15-LOX then oxygenates at C15 β 4S,5-epoxide intermediate β enzymatic hydrolysis β RvD4 with characteristic 4S,5R,17S-trihydroxy stereochemistry.
-
Receptor Engagement: RvD4 binds specific G-protein coupled receptors (likely overlapping with other D-series resolvins including ALX/FPR2 and potentially DRV1/GPR32, though RvD4's receptor profile is still being characterized). Binding occurs at picomolar to nanomolar concentrations (ECβ
β ~1-10 nM).
-
Anti-Neutrophil Recruitment: RvD4 β receptor activation β inhibition of NF-ΞΊB translocation β β expression of endothelial adhesion molecules (VCAM-1, E-selectin) β reduced neutrophil extravasation from circulation β lower Ξ¨_max in the resolution interval.
-
Pro-Efferocytosis Signaling: RvD4 β macrophage receptor β activation of Akt and ERK pathways β β expression of engulfment receptors β enhanced recognition and uptake of apoptotic cells β accelerated clearance phase (β Tβ
β).
-
Cytokine Regulation: RvD4 β intracellular signaling β suppression of IL-1Ξ², TNF-Ξ±, IL-6 transcription β β anti-inflammatory IL-10 release β shift from pro-inflammatory to pro-resolution phenotype.
-
Antimicrobial Enhancement: RvD4 preserves host defense by enhancing bacterial phagocytosis and killing while simultaneously reducing collateral tissue damage from inflammatory mediators.
-
Tissue Repair: RvD4 β β expression of growth factors (TGF-beta, VEGF) β stimulation of fibroblast migration and collagen synthesis β organized tissue remodeling rather than fibrotic scarring.
RvD4 represents a crucial therapeutic target in any condition where inflammatory resolution is impaired or incomplete. Its deficit creates the clinical picture of chronic low-grade inflammation (Metaflammation) β the substrate for most modern chronic diseases.
Relevant Patient Populations:
Metamodel Integration:
- Metamodel 0 (Evolutionary Mismatch): Modern Western diets provide insufficient DHA substrate (~100-200 mg/day vs. ancestral 600-1000 mg/day), creating SPM deficiency despite normal enzymatic machinery.
- Metamodel 1 (Selfish Systems): The Selfish Immune System can become trapped in pro-inflammatory mode when resolution signals like RvD4 are absent β prioritizing immediate threat response over long-term tissue health.
- Metamodel 3 (Energy Distribution): Chronic inflammation from failed resolution creates energy drain toward immune activation at expense of ATP production and muscle mass.
Clinical Thresholds:
Intervention Implications:
- Stereospecific structure: 4S,5R,17S-trihydroxy configuration is essential for bioactivity; other isomers are inactive or antagonistic
- Active concentration range: Effective at 1-100 nM (nanomolar) β roughly 1000-fold more potent than NSAIDs on a molar basis
- Biosynthetic requirement: Requires adequate DHA (>8% of total fatty acids in membrane phospholipids) plus functional 5-LOX and 15-LOX enzyme systems
- Half-life: Rapid metabolic inactivation (~15-30 minutes) via oxidation and Ξ²-oxidation ensures temporal control of resolution
- Part of D-series family: RvD4 is one of six characterized D-series resolvins (RvD1 through RvD6), each with distinct receptor profiles and bioactions
- Cross-system effects: Reduces neuroinflammation in microglia, adipose inflammation in adipocytes, and joint inflammation in synovial fluid
- Non-immunosuppressive: Preserves antimicrobial responses and innate immunity while terminating inflammation
- Temperature sensitive: Biosynthesis is optimal at normal body temperature (37Β°C); fever (>38.5Β°C) can impair SPM enzyme activity
- Lipidomics detection: Requires LC-MS/MS with multiple reaction monitoring for accurate quantification; not detected by standard fatty acid panels
- Evolutionary conservation: D-series resolvin biosynthetic pathways appear in fish, suggesting ancient origin tied to marine Omega-3 metabolism
- DHA β RvD4 is biosynthesized exclusively from DHA via sequential lipoxygenation; inadequate DHA substrate abolishes RvD4 production
- Specialized pro-resolving mediators (SPMs) β RvD4 is member of SPM superfamily alongside resolvins, protectins, maresins, and lipoxins
- Resolvin D-series β RvD4 is one of six characterized D-series resolvins sharing DHA substrate but distinct stereochemistry and receptor profiles
- RvD1 β Sister molecule in D-series with better-characterized receptor (ALX-FPR2, DRV1/GPR32) and slightly different tissue distribution
- Resolution of inflammation β RvD4 actively terminates inflammatory response through receptor-mediated cellular reprogramming
- Lipoxygenase β Both 5-LOX and 15-LOX are required sequentially for RvD4 biosynthesis from DHA
- 5-LOX β Catalyzes first oxygenation step (C4 position) in RvD4 biosynthetic pathway
- 15-LOX β Catalyzes second oxygenation step (C17 position) completing RvD4 structure
- Lipid mediator class switching β RvD4 production represents metabolic switch from pro-inflammatory eicosanoids to pro-resolution SPMs
- Efferocytosis β RvD4 enhances macrophage uptake of apoptotic neutrophils, accelerating resolution phase
- Neutrophil β RvD4 blocks neutrophil recruitment and promotes neutrophil apoptosis and clearance
- NF-ΞΊB β RvD4 inhibits NF-ΞΊB nuclear translocation, reducing pro-inflammatory gene transcription
- IL-6 β RvD4 suppresses IL-6 production from macrophages and adipocytes
- TNF-Ξ± β RvD4 reduces TNF-Ξ± synthesis and release from activated immune cells
- IL-10 β RvD4 stimulates IL-10 production, creating anti-inflammatory feedback loop
- Omega-3 index β Erythrocyte EPA+DHA percentage predicts SPM biosynthetic capacity; <4% indicates deficiency
- Omega-6 to omega-3 ratio β High ratios (>10:1) competitively inhibit RvD4 biosynthesis via substrate competition at lipoxygenase enzymes
- Aspirin-triggered resolvins β Aspirin-acetylated COX-2 produces 17R-RvD epimers with similar pro-resolution activity
- COX-2 β When acetylated by aspirin, generates 17R-hydroxy-DHA intermediates for aspirin-triggered D-series resolvins
- Macrophage Polarization β RvD4 promotes M2-like phenotype with enhanced efferocytosis and tissue repair functions
- Chronic inflammation β RvD4 deficiency contributes to failure of inflammatory resolution creating chronic low-grade inflammatory state
- Metaflammation β Insufficient RvD4 production allows metabolic inflammation to persist in adipose tissue and liver
- Type 2 Diabetes β Low plasma RvD4 correlates with insulin resistance and adipose inflammation in diabetic patients
- Obesity β Adipose tissue from obese individuals shows impaired RvD4 biosynthesis despite adequate DHA substrate
- Inflammatory bowel disease β Mucosal RvD4 levels are markedly reduced in active IBD; supplementation shows therapeutic promise
- Wound healing β RvD4 accelerates tissue repair phase while preventing excessive fibrosis
- Atherosclerosis β Vascular RvD4 deficiency promotes plaque progression and unstable lesion formation
- Central sensitization β Spinal RvD4 administration reduces neuroinflammation-driven pain amplification
- Neuroinflammation β RvD4 crosses blood-brain barrier and reduces microglial activation in CNS
- Resolution interval (R_i) β RvD4 shortens R_i by accelerating neutrophil apoptosis and clearance
- Ξ¨_max (peak PMN infiltration) β RvD4 reduces Ξ¨_max by blocking neutrophil recruitment signals
- Tβ
β β RvD4 decreases Tβ
β (time to 50% neutrophil reduction) via enhanced efferocytosis
- Immune suppression β Unlike immunosuppressive drugs, RvD4 preserves antimicrobial immunity while resolving inflammation